Double-blind randomized comparison of intravenous tocainide versus lidocaine in the treatment of chronic ventricular arrhythmias

Syed M. Mohiuddin, Daniel E. Hilleman, Aryan N. Mooss, Dennis J. Esterbrooks, Michael H. Sketch, Lois A. Stengel, Mary L. Butler

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

The efficacy and safety of intravenous tocainide were compared with intravenous lidocaine in patients with chronic ventricular arrhythmias in a double-blind, parallel study. Twenty-nine patients were randomized to a tocainide (n = 15) or lidocaine (n = 14) group. Antiarrhythmic efficacy was defined as a ≥50% reduction in single ventricular premature complex (VPC) frequency, ≥90% reduction in paired VPC frequency, and total abolition of ventricular tachycardia. Efficacy was observed in 40% (6 of 15) of patients in the tocainide group and in 36% (5 of 14) patients in the lidocaine group. A 75% or greater reduction in total VPCs occurred in 40% (6 of 15) of patients in the tocainide group and in 57% (8 of 14) of patients in the lidocaine group. Greater than 90% suppression of paired VPCs occurred in 9 of 13 (69%) patients taking tocainide and in 6 of 11 (54%) patients taking lidocaine. Total abolition of ventricular tachycardia was documented in 5 of 11 (45%) patients given tocainide and in two of six (33%) patients given lidocaine. A total of 17 adverse reactions affecting 86% (12 of 14) of patients taking lidocaine and 11 adverse reactions affecting 53% (8 of 15) of patients taking tocainide occurred. Four patients in each treatment group suffered dose-limiting adverse effects. This study suggests that the efficacy and safety of intravenous tocainide are similar to that of intravenous lidocaine in patients with chronic ventricular arrhythmias.

Original languageEnglish
Pages (from-to)296-302
Number of pages7
JournalAmerican Heart Journal
Volume114
Issue number2
DOIs
StatePublished - 1987

Fingerprint

Tocainide
Lidocaine
Cardiac Arrhythmias
Therapeutics
Ventricular Premature Complexes
Ventricular Tachycardia
Safety

All Science Journal Classification (ASJC) codes

  • Cardiology and Cardiovascular Medicine

Cite this

@article{698bec94cf5f4477a78a83e3ddb52d8f,
title = "Double-blind randomized comparison of intravenous tocainide versus lidocaine in the treatment of chronic ventricular arrhythmias",
abstract = "The efficacy and safety of intravenous tocainide were compared with intravenous lidocaine in patients with chronic ventricular arrhythmias in a double-blind, parallel study. Twenty-nine patients were randomized to a tocainide (n = 15) or lidocaine (n = 14) group. Antiarrhythmic efficacy was defined as a ≥50{\%} reduction in single ventricular premature complex (VPC) frequency, ≥90{\%} reduction in paired VPC frequency, and total abolition of ventricular tachycardia. Efficacy was observed in 40{\%} (6 of 15) of patients in the tocainide group and in 36{\%} (5 of 14) patients in the lidocaine group. A 75{\%} or greater reduction in total VPCs occurred in 40{\%} (6 of 15) of patients in the tocainide group and in 57{\%} (8 of 14) of patients in the lidocaine group. Greater than 90{\%} suppression of paired VPCs occurred in 9 of 13 (69{\%}) patients taking tocainide and in 6 of 11 (54{\%}) patients taking lidocaine. Total abolition of ventricular tachycardia was documented in 5 of 11 (45{\%}) patients given tocainide and in two of six (33{\%}) patients given lidocaine. A total of 17 adverse reactions affecting 86{\%} (12 of 14) of patients taking lidocaine and 11 adverse reactions affecting 53{\%} (8 of 15) of patients taking tocainide occurred. Four patients in each treatment group suffered dose-limiting adverse effects. This study suggests that the efficacy and safety of intravenous tocainide are similar to that of intravenous lidocaine in patients with chronic ventricular arrhythmias.",
author = "Mohiuddin, {Syed M.} and Hilleman, {Daniel E.} and Mooss, {Aryan N.} and Esterbrooks, {Dennis J.} and Sketch, {Michael H.} and Stengel, {Lois A.} and Butler, {Mary L.}",
year = "1987",
doi = "10.1016/0002-8703(87)90494-7",
language = "English",
volume = "114",
pages = "296--302",
journal = "American Heart Journal",
issn = "0002-8703",
publisher = "Mosby Inc.",
number = "2",

}

TY - JOUR

T1 - Double-blind randomized comparison of intravenous tocainide versus lidocaine in the treatment of chronic ventricular arrhythmias

AU - Mohiuddin, Syed M.

AU - Hilleman, Daniel E.

AU - Mooss, Aryan N.

AU - Esterbrooks, Dennis J.

AU - Sketch, Michael H.

AU - Stengel, Lois A.

AU - Butler, Mary L.

PY - 1987

Y1 - 1987

N2 - The efficacy and safety of intravenous tocainide were compared with intravenous lidocaine in patients with chronic ventricular arrhythmias in a double-blind, parallel study. Twenty-nine patients were randomized to a tocainide (n = 15) or lidocaine (n = 14) group. Antiarrhythmic efficacy was defined as a ≥50% reduction in single ventricular premature complex (VPC) frequency, ≥90% reduction in paired VPC frequency, and total abolition of ventricular tachycardia. Efficacy was observed in 40% (6 of 15) of patients in the tocainide group and in 36% (5 of 14) patients in the lidocaine group. A 75% or greater reduction in total VPCs occurred in 40% (6 of 15) of patients in the tocainide group and in 57% (8 of 14) of patients in the lidocaine group. Greater than 90% suppression of paired VPCs occurred in 9 of 13 (69%) patients taking tocainide and in 6 of 11 (54%) patients taking lidocaine. Total abolition of ventricular tachycardia was documented in 5 of 11 (45%) patients given tocainide and in two of six (33%) patients given lidocaine. A total of 17 adverse reactions affecting 86% (12 of 14) of patients taking lidocaine and 11 adverse reactions affecting 53% (8 of 15) of patients taking tocainide occurred. Four patients in each treatment group suffered dose-limiting adverse effects. This study suggests that the efficacy and safety of intravenous tocainide are similar to that of intravenous lidocaine in patients with chronic ventricular arrhythmias.

AB - The efficacy and safety of intravenous tocainide were compared with intravenous lidocaine in patients with chronic ventricular arrhythmias in a double-blind, parallel study. Twenty-nine patients were randomized to a tocainide (n = 15) or lidocaine (n = 14) group. Antiarrhythmic efficacy was defined as a ≥50% reduction in single ventricular premature complex (VPC) frequency, ≥90% reduction in paired VPC frequency, and total abolition of ventricular tachycardia. Efficacy was observed in 40% (6 of 15) of patients in the tocainide group and in 36% (5 of 14) patients in the lidocaine group. A 75% or greater reduction in total VPCs occurred in 40% (6 of 15) of patients in the tocainide group and in 57% (8 of 14) of patients in the lidocaine group. Greater than 90% suppression of paired VPCs occurred in 9 of 13 (69%) patients taking tocainide and in 6 of 11 (54%) patients taking lidocaine. Total abolition of ventricular tachycardia was documented in 5 of 11 (45%) patients given tocainide and in two of six (33%) patients given lidocaine. A total of 17 adverse reactions affecting 86% (12 of 14) of patients taking lidocaine and 11 adverse reactions affecting 53% (8 of 15) of patients taking tocainide occurred. Four patients in each treatment group suffered dose-limiting adverse effects. This study suggests that the efficacy and safety of intravenous tocainide are similar to that of intravenous lidocaine in patients with chronic ventricular arrhythmias.

UR - http://www.scopus.com/inward/record.url?scp=0023387515&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023387515&partnerID=8YFLogxK

U2 - 10.1016/0002-8703(87)90494-7

DO - 10.1016/0002-8703(87)90494-7

M3 - Article

C2 - 3111238

AN - SCOPUS:0023387515

VL - 114

SP - 296

EP - 302

JO - American Heart Journal

JF - American Heart Journal

SN - 0002-8703

IS - 2

ER -